Today, Gennao Bio, a private genetic medicine enterprise pioneering targeted nucleic acid therapies, revealed fresh preclinical findings regarding the use of its non-viral, cell-penetrating gene monoclonal antibody (GMAB) platform technology. These results showcase its potential as an antibody-drug conjugate (ADC) for solid tumor treatment. The data were unveiled in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024.
Gennao Bio, a leader in genetic medicines, has unveiled promising exploratory research on the potential of its non-viral, cell-penetrating gene monoclonal antibody (GMAB) platform technology as an antibody-drug conjugate (ADC) for solid tumor treatment. The study, conducted in collaboration with Dr. Peter M. Glazer’s laboratory at Yale School of Medicine, showcased GMAB’s ability to selectively deliver cytotoxic payloads into tumors by targeting ENT2, a nucleoside transporter overexpressed in many tumors. Preclinical studies demonstrated GMAB’s efficacy in delivering payloads directly into tumor cells’ cytoplasm and nucleus, bypassing harmful pathways and leading to tumor cell death. Dr. Glazer highlighted the promising potential of GMAB ADC in tumor regression and safety, supporting its further investigation.
In a preclinical study on colorectal cancer, GMAB ADC displayed significant tumor regression and survival benefits compared to controls and standalone exatecan, with no observed toxicity in vital organs like the kidney and liver. These results underscore GMAB’s versatility and safety profile, paving the way for further optimization and clinical exploration.
Chris Duke, CEO of Gennao, emphasized the platform’s adaptability and potential to revolutionize cancer treatment, promising novel therapeutic options for patients. Gennao Bio focuses on developing targeted nucleic acid therapeutics using GMAB technology, offering a novel approach to address skeletal muscle diseases and oncology.
